FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W20146419> ?p ?o ?g. }

• W20146419 endingPage "433" @default.
• W20146419 startingPage "424" @default.
• W20146419 abstract "The aim of this study was to examine the efficacy and bleeding outcomes of cangrelor in patients in the CHAMPION PHOENIX (A Clinical Trial Comparing Cangrelor to Clopidogrel Standard Therapy in Subjects Who Require Percutaneous Coronary Intervention [PCI]) who underwent percutaneous coronary intervention with bivalirudin.Cangrelor is a potent intravenous P2Y12 inhibitor with rapid onset and offset. In the CHAMPION PHOENIX, cangrelor compared with clopidogrel significantly reduced 48-h ischemic events including stent thrombosis, without increasing major bleeding. Bivalirudin has demonstrated ischemic outcomes similar to those with heparin plus glycoprotein IIb/IIIa inhibition, with reduced bleeding but increased early stent thrombosis.In the modified intent-to-treat population, 2,059 patients (18.8%) received bivalirudin, with 1,014 patients in the cangrelor treatment arm and 1,045 in the clopidogrel treatment arm.At 48 h, the primary endpoint of death, myocardial infarction, ischemia-driven revascularization, or stent thrombosis was lower with cangrelor versus clopidogrel (48 [4.7%] vs. 70 [6.7%]; odds ratio [OR]: 0.68, p = 0.047). Death was similar in both arms (2 [0.2%] vs. 2 [0.2%]). Myocardial infarction was reduced by cangrelor (37 [3.6%] vs. 59 [5.6%]; OR: 0.63, p = 0.03), as was death/myocardial infarction (39 [3.8%] vs. 61 [5.8%]; OR: 0.65, p = 0.04). Cangrelor was associated with a nonsignificant trend toward less stent thrombosis (7 [0.7%] vs. 15 [1.4%]; OR: 0.48, p = 0.10), which was evident within 2 h after percutaneous coronary intervention (p = 0.057). GUSTO (Global Use of Strategies to Open Occluded Arteries) severe bleeding was similar in both arms (2 of 1,021 [0.2%] vs. 2 of 1,055 [0.2%]) as were other bleeding definitions and transfusions. Efficacy and safety results were consistent in patients with stable angina, non-ST-segment elevation acute coronary syndrome, and ST-segment elevation myocardial infarction (p for interaction: 0.62 and 0.29).Cangrelor may offer an attractive benefit risk profile when used in combination with bivalirudin." @default.
• W20146419 created "2016-06-24" @default.
• W20146419 creator A5003831287 @default.
• W20146419 creator A5007026783 @default.
• W20146419 creator A5010571732 @default.
• W20146419 creator A5010936003 @default.
• W20146419 creator A5039432822 @default.
• W20146419 creator A5046629853 @default.
• W20146419 creator A5049504035 @default.
• W20146419 creator A5060370891 @default.
• W20146419 creator A5062843291 @default.
• W20146419 creator A5065179446 @default.
• W20146419 creator A5065347832 @default.
• W20146419 creator A5069820090 @default.
• W20146419 creator A5086306721 @default.
• W20146419 creator A5091015866 @default.
• W20146419 date "2015-03-01" @default.
• W20146419 modified "2023-10-05" @default.
• W20146419 title "Outcomes With Cangrelor Versus Clopidogrel on a Background of Bivalirudin" @default.
• W20146419 cites W152096358 @default.
• W20146419 cites W1538704194 @default.
• W20146419 cites W2020190643 @default.
• W20146419 cites W2020353475 @default.
• W20146419 cites W2050027713 @default.
• W20146419 cites W2080802732 @default.
• W20146419 cites W2087150869 @default.
• W20146419 cites W2090749073 @default.
• W20146419 cites W2103428481 @default.
• W20146419 cites W2110108344 @default.
• W20146419 cites W2114758846 @default.
• W20146419 cites W2121251309 @default.
• W20146419 cites W2142825093 @default.
• W20146419 cites W2148678963 @default.
• W20146419 cites W2150655309 @default.
• W20146419 cites W2153447053 @default.
• W20146419 cites W2156927593 @default.
• W20146419 cites W2166950143 @default.
• W20146419 cites W2168874562 @default.
• W20146419 cites W2170029016 @default.
• W20146419 cites W4293372203 @default.
• W20146419 doi "https://doi.org/10.1016/j.jcin.2014.09.025" @default.
• W20146419 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25703887" @default.
• W20146419 hasPublicationYear "2015" @default.
• W20146419 type Work @default.
• W20146419 sameAs 20146419 @default.
• W20146419 citedByCount "34" @default.
• W20146419 countsByYear W201464192015 @default.
• W20146419 countsByYear W201464192016 @default.
• W20146419 countsByYear W201464192017 @default.
• W20146419 countsByYear W201464192018 @default.
• W20146419 countsByYear W201464192019 @default.
• W20146419 countsByYear W201464192020 @default.
• W20146419 countsByYear W201464192022 @default.
• W20146419 countsByYear W201464192023 @default.
• W20146419 crossrefType "journal-article" @default.
• W20146419 hasAuthorship W20146419A5003831287 @default.
• W20146419 hasAuthorship W20146419A5007026783 @default.
• W20146419 hasAuthorship W20146419A5010571732 @default.
• W20146419 hasAuthorship W20146419A5010936003 @default.
• W20146419 hasAuthorship W20146419A5039432822 @default.
• W20146419 hasAuthorship W20146419A5046629853 @default.
• W20146419 hasAuthorship W20146419A5049504035 @default.
• W20146419 hasAuthorship W20146419A5060370891 @default.
• W20146419 hasAuthorship W20146419A5062843291 @default.
• W20146419 hasAuthorship W20146419A5065179446 @default.
• W20146419 hasAuthorship W20146419A5065347832 @default.
• W20146419 hasAuthorship W20146419A5069820090 @default.
• W20146419 hasAuthorship W20146419A5086306721 @default.
• W20146419 hasAuthorship W20146419A5091015866 @default.
• W20146419 hasBestOaLocation W201464191 @default.
• W20146419 hasConcept C126322002 @default.
• W20146419 hasConcept C164705383 @default.
• W20146419 hasConcept C2776708134 @default.
• W20146419 hasConcept C2777565915 @default.
• W20146419 hasConcept C2777849778 @default.
• W20146419 hasConcept C2780400711 @default.
• W20146419 hasConcept C42219234 @default.
• W20146419 hasConcept C45393284 @default.
• W20146419 hasConcept C49059817 @default.
• W20146419 hasConcept C500558357 @default.
• W20146419 hasConcept C71924100 @default.
• W20146419 hasConceptScore W20146419C126322002 @default.
• W20146419 hasConceptScore W20146419C164705383 @default.
• W20146419 hasConceptScore W20146419C2776708134 @default.
• W20146419 hasConceptScore W20146419C2777565915 @default.
• W20146419 hasConceptScore W20146419C2777849778 @default.
• W20146419 hasConceptScore W20146419C2780400711 @default.
• W20146419 hasConceptScore W20146419C42219234 @default.
• W20146419 hasConceptScore W20146419C45393284 @default.
• W20146419 hasConceptScore W20146419C49059817 @default.
• W20146419 hasConceptScore W20146419C500558357 @default.
• W20146419 hasConceptScore W20146419C71924100 @default.
• W20146419 hasFunder F4320307765 @default.
• W20146419 hasFunder F4320307773 @default.
• W20146419 hasFunder F4320307779 @default.
• W20146419 hasFunder F4320307781 @default.
• W20146419 hasFunder F4320309517 @default.
• W20146419 hasFunder F4320315027 @default.

• next